About the project
About Tesa Peptides
A reading of the tesamorelin literature laid out like a research curriculum — module by module, each figure cited to source.
What Tesa Peptides Is
Tesa Peptides works through the peer-reviewed tesamorelin literature the way you would work through a study syllabus — reading each trial, glossing the peptide science in plain English, and building the record module by module. It sees no patients and writes no prescriptions; there is no clinic, no pharmacy, and nothing here to purchase. The pages summarize published science and cite every figure to source; they do not diagnose, treat, or tell anyone what to do.
The "peptides" in the name is editorial framing — a position this publisher occupies relative to the literature, signaling that we read tesamorelin first as a peptide-science subject (what the molecule is, how it works, what the trials measured) rather than as a product to be acquired. It is not a claim that this site offers any service, treatment, or sale.
How We Read the Literature
We treat tesamorelin's evidence base as a curriculum because it genuinely reads like one: a synthetic GHRH(1-44) analogue whose record builds in clear milestones — the receptor mechanism, the 2007 pivotal visceral-fat RCT, the 52-week durability program, the JAMA 2014 hepatic-fat trial, the 2010 FDA approval, and the 2026 five-RCT meta-analysis [1][2][3][5][12].
Every quantitative claim on this site is tagged to a numbered source on the full reference list. Where the evidence is strong — the pivotal human RCTs — we say so plainly. Where it is thin or absent — the missing non-HIV fat-loss trial, the reaccumulation of fat after discontinuation — we mark the gap rather than paper over it. The goal is a digest that flags the limits of the record as prominently as its findings.
Is Tesamorelin FDA Approved?
Yes, but narrowly. Tesamorelin was FDA-approved in 2010 (NDA 022505) to reduce excess abdominal visceral fat in HIV-infected adults with lipodystrophy [5]. There is no FDA indication outside HIV-associated lipodystrophy; every other use is off-label. It is also prohibited in sport under WADA category S2. We state this scope precisely throughout the site — neither overstating the approval (it is real) nor understating it (it is narrow).
On Scope and Accuracy
This digest reports only what the cited tesamorelin literature establishes, in the populations it was studied in — overwhelmingly HIV-positive adults on antiretroviral therapy [1][2][3]. We do not extrapolate trial findings to general or cosmetic use, and we describe research findings rather than recommend any course of action. Research-grade tesamorelin sold for laboratory use is not the approved finished drug product and lacks its purity and potency oversight. Corrections and source questions are welcome via the contact page.